Leo Fondet 2021 AR2
The report highlights the LEO Group's performance in 2021, marked by the establishment of a new ownership structure for LEO Pharma with Nordic Capital as a partner. LEO Pharma achieved key milestones, including the approval of tralokinumab in the EU and US for moderate-to-severe atopic dermatitis. The LEO Foundation increased its philanthropic support for skin research to DKK 163 million, supported by a 13.6% return on financial investments. Additionally, LEO Pharma reduced its carbon emissions by 25.7% by switching to 100% renewable electricity and submitted climate targets to the Science Based Targets initiative.
Company: Leo Fondet
Sector: Finance & insurance
Country: Denmark
Year: 2021
Type: AR2
Pages: 86
Back to company
Leo Fondet
Annual Report
The report highlights the LEO Group's performance in 2021, marked by the establishment of a new ownership structure for LEO Pharma with Nordic Capital as a partner. LEO Pharma achieved key milestones, including the approval of tralokinumab in the EU and US for moderate-to-severe atopic dermatitis. The LEO Foundation increased its philanthropic support for skin research to DKK 163 million, supported by a 13.6% return on financial investments. Additionally, LEO Pharma reduced its carbon emissions by 25.7% by switching to 100% renewable electricity and submitted climate targets to the Science Based Targets initiative.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Women in Management
Employees